​

Celldex Therapeutics (CLDX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CLDX Stock Forecast

Celldex Therapeutics (CLDX) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $24.00, with a high of $24.00 and a low of $24.00. This represents a -19.68% decline from the last price of $29.88.

$20 $26 $32 $38 $44 $50 High: $24 Avg: $24 Low: $24 Last Closed Price: $29.88

CLDX Stock Rating

Celldex Therapeutics stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (73.68%), 4 Hold (21.05%), 1 Sell (5.26%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 1 4 14 Strong Sell Sell Hold Buy Strong Buy

CLDX Price Target Upside V Benchmarks

TypeNameUpside
StockCelldex Therapeutics-19.68%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-14
Avg Price Target-$24.00$29.00
Last Closing Price$29.88$29.88$29.88
Upside/Downside--19.68%-2.95%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 261122-116
Feb, 261122-116
Jan, 261122-116
Dec, 251122-116
Nov, 252112-116
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 17, 2025Barclays$24.00$26.68-10.04%-19.68%
Nov 11, 2025Barclays$21.00$22.67-7.37%-29.72%
Oct 13, 2025Barclays$25.00$26.77-6.61%-16.33%
Mar 20, 2025Morgan Stanley$46.00$19.88131.39%53.95%
Oct 29, 2024Joseph PantginisH.C. Wainwright$80.00$27.12194.99%167.74%
Sep 25, 2024Derek ArchilaWells Fargo$44.00$36.0222.15%47.26%
Jun 17, 2024Alex ThompsonStifel Nicolaus$58.00$34.9166.14%94.11%
Nov 10, 2023Derek ArchilaWells Fargo$27.00$25.784.73%-9.64%
Nov 11, 2022Guggenheim$63.00$39.8957.93%110.84%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 13, 2025BarclaysUnderweightinitialise
Mar 20, 2025Morgan StanleyOverweightinitialise
Jan 08, 2025CitigroupBuyBuyhold
Oct 29, 2024H.C. WainwrightBuyBuyhold
Oct 28, 2024Cowen & Co.BuyBuyhold
Oct 28, 2024Wolfe ResearchBuyBuyhold
Oct 28, 2024GuggenheimBuyBuyhold
Oct 07, 2024CitigroupBuyinitialise
Sep 30, 2024Goldman SachsNeutralinitialise
Sep 27, 2024Leerink PartnersMarket Performdowngrade

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.64$-2.40$-2.92$-2.45$-3.90---
Avg Forecast$-1.64$-2.38$-2.80$-2.45$-3.28$-3.79$-3.75$-1.07
High Forecast$-0.84$-1.61$-2.60$-2.35$-2.93$-2.85$-3.15$-0.61
Low Forecast$-2.97$-3.71$-2.95$-2.59$-3.55$-4.82$-4.28$-1.74
Surprise %-0.84%4.29%-18.90%---

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.65M$2.36M$6.88M$7.02M$1.54M---
Avg Forecast$5.34M$988.00K$4.11M$6.83M$4.00M$2.84M$51.13M$328.93M
High Forecast$8.67M$1.41M$4.95M$8.32M$5.95M$2.85M$76.03M$489.11M
Low Forecast$3.34M$742.71K$3.22M$5.67M$2.68M$2.82M$34.22M$220.10M
Surprise %-12.90%138.56%67.57%2.80%-61.42%---

Net Income Forecast

$-300M $-240M $-180M $-120M $-60M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-70.51M$-112.33M$-141.43M$-157.86M$-258.76M---
Avg Forecast$-79.46M$-86.68M$-141.43M$-119.81M$-157.14M$-185.74M$-180.08M$-51.60M
High Forecast$-40.83M$-69.35M$-113.14M$-114.06M$-142.17M$-138.09M$-152.63M$-29.41M
Low Forecast$-143.95M$-104.02M$-169.71M$-125.56M$-172.12M$-233.39M$-207.53M$-84.26M
Surprise %-11.26%29.58%-31.76%64.66%---

CLDX Forecast FAQ

Is Celldex Therapeutics stock a buy?

Celldex Therapeutics stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Celldex Therapeutics is a favorable investment for most analysts.

What is Celldex Therapeutics's price target?

Celldex Therapeutics's price target, set by 19 Wall Street analysts, averages $24 over the next 12 months. The price target range spans from $24 at the low end to $24 at the high end, suggesting a potential -19.68% change from the previous closing price of $29.88.

How does Celldex Therapeutics stock forecast compare to its benchmarks?

Celldex Therapeutics's stock forecast shows a -19.68% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Celldex Therapeutics over the past three months?

  • March 2026: 6.25% Strong Buy, 75.00% Buy, 12.50% Hold, 0% Sell, 6.25% Strong Sell.
  • February 2026: 6.25% Strong Buy, 75.00% Buy, 12.50% Hold, 0% Sell, 6.25% Strong Sell.
  • January 2026: 6.25% Strong Buy, 75.00% Buy, 12.50% Hold, 0% Sell, 6.25% Strong Sell.

What is Celldex Therapeutics’s EPS forecast?

Celldex Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.79, marking a -2.82% decrease from the reported $-3.9 in 2025. Estimates for the following years are $-3.75 in 2027, and $-1.07 in 2028.

What is Celldex Therapeutics’s revenue forecast?

Celldex Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $2.84M, reflecting a 83.62% increase from the reported $1.54M in 2025. The forecast for 2027 is $51.13M, and $328.92M for 2028.

What is Celldex Therapeutics’s net income forecast?

Celldex Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-186M, representing a -28.22% decrease from the reported $-259M in 2025. Projections indicate $-180M in 2027, and $-51.598M in 2028.